Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068846 · ClinicalTrials.gov registry record · Phase 3
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
A Phase 3 study of HIV and Salivary Gland Disease, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT02068846: Completed Phase 3 study of HIV and Salivary Gland Disease, sponsored by University of North Carolina, Chapel Hill.
NCT02068846 is a Phase 3 study of HIV and Salivary Gland Disease that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 17 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02068846, a Phase 3 study of HIV and Salivary Gland Disease, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary function/protein secretion will be correlated with BK polyomavirus titers. It is expected that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit from Ciprofloxacin.
Primary Outcome
Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin
Study Locations (1)
North Carolina
- The University of North Carolina School of Dentistry - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
What the finished NCT02068846 record still lists
NCT02068846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02068846 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02068846 about?
NCT02068846 is a clinical study titled "BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent". The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (...
What is the current status of trial NCT02068846?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2014-04. Estimated completion is 2016-01.
What conditions does trial NCT02068846 study?
This clinical trial studies the following conditions: HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion.
What interventions are being tested in trial NCT02068846?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin (DRUG).
Who is sponsoring clinical trial NCT02068846?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02068846 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02068846's enrollment target sits among peer trials
17 287th of 303 higher than 17 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
COMPLETED · Phase 3
-
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
COMPLETED · Phase 3
-
Effects of Biktarvy on CFR in Stable HIV Patients
COMPLETED · Phase 3
-
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
COMPLETED · Phase 3
-
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia